BioMarin struck a deal up to $475 million for HM15421/GC1134A, a Fabry disease enzyme replacement therapy designed to extend drug exposure via Hanmi’s long-acting drug technology. BioMarin received worldwide rights, while GC and Hanmi retain key roles for Korea commercialization and regulatory efforts, with milestone payments potentially reaching $405 million tied to future development and sales outcomes.